Arguably, targeting activating mutations in the phosphoinoside-3-kinase (PI3K)/AKT pathway have proven to be a viable strategy for inhibiting mTOR, however, in cancers that are mutant for LKB1 [3], AMPK-mediated regulation of mTOR will be compromised. This evidence concerns the gene MTOR and cancer.